US Investigator Meeting Held for Ph 3 HLX22-GC-301 in HER2+ Gastric Cancer
Jing Li, Vice President of Global Product Development at Henlius, said: “The U.S. investigator team plays a critical role in trial design interpretation, patient management, and execution quality for HLX22-GC-301. This investigator meeting provided an important platform for alignment and in-depth communication across sites, helping to further enhance consistency and standardization of trial implementation across regions. Henlius will continue to advance global clinical development to the highest standards, working closely with our international investigator partners to accelerate the global clinical validation and value realization of the differentiated innovative asset HLX22.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines